Pharmacotherapy for Patients with Obesity

Area of Science:

• Pharmacology
• Obesity Medicine
• Clinical Research

Background:

• Pharmacotherapy is a supplementary tool for obesity treatment, particularly for patients unresponsive to lifestyle interventions or struggling with weight maintenance.
• Current obesity pharmacotherapy is not a primary treatment but aids patients with persistent weight management challenges.

Purpose of the Study:

• To review the role, mechanisms, targets, history, and clinical application of antiobesity drugs.
• To summarize efficacy and safety data from clinical trials of weight management medications.

Main Methods:

• Review of available antiobesity drugs and their pharmacological targets.
• Analysis of clinical trial data, including efficacy (weight loss) and safety profiles.
• Examination of regulatory approval criteria and limitations of trial data interpretation.

Main Results:

• Five antiobesity drugs are approved in the US for long-term weight management.
• Only two drugs meet stricter FDA criteria for 5% weight loss; others use categorical criteria.
• High dropout rates in trials limit generalizability, and cost/insurance issues hinder patient access.

Conclusions:

• The US has expanded pharmacotherapy options for obesity since 2012.
• Improvements in clinical investigation quality are needed, focusing on response mediators and moderators.
• Addressing access barriers like cost and insurance coverage is crucial for effective pharmacotherapy implementation.